{"ok":true,"trend":{"id":518224,"platform":"news","region":"global","key":"pharmacy compounding under the eu pharma law package – what marketing authorisation holders and innovators need to know","title":"Pharmacy compounding under the EU pharma law package – What marketing authorisation holders and innovators need to know","url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQcG9WWm5rNTJKbjJBY2dvQ0pHOFdFYjRoSTdTbm4telhPNkMxSjh4N01tYTFBd1N5cHA2ZDBob2l0bHpaYmdHelhJbXdaQXVTV0VmRnlPS2dvLTRwaFBoOFNBbUJkcEVJZzVaenZhQXlsbnBGbmJoVHdpeG44MTFWUVczMTBXN0JHWHhiQVM0T3FTem1ZX2xDWTk5X3ZFSC14R1VVa1pLRVhKX0xHSTBCc0FUSjdJZGlGTURaTjVEMENLMEE?oc=5","first_seen":"2026-09-30T19:14:53.274433Z","last_seen":"2026-09-30T23:21:12.042922Z","last_rank":25,"peak_rank":12,"last_volume":null,"peak_volume":0,"seen_count":4,"score":0.9621875,"category_hint":"eu_politics","section":"world","category":"eu_politics","summary":"Legal analysis is examining how the EU's pharmaceutical legislation reform package treats pharmacy compounding, and what that means for marketing authorisation holders and innovator companies. The guidance highlights how changes to the rules could affect exemptions for compounded medicines, competition from pharmacies, and how manufacturers protect their products' position in the EU market.","why":"The EU's reform of pharmaceutical legislation is prompting companies and lawyers to assess how new compounding rules will affect their market exclusivity and obligations.","tone":"neutral","entities":["European Union"],"summarized_at":"2026-10-01T01:18:37.840395Z","meta":{"via":"scan","lang":"en","term":"european union","source":"www.hlc.com","published":"Wed, 30 Sep 2026 17:31:02 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"EU pharma law package puts pharmacy compounding in focus","section_name":"World","category_name":"EU Politics","timeline":[{"captured_at":"2026-09-30T19:14:53.274433Z","rank":13,"volume":null},{"captured_at":"2026-09-30T20:37:12.270607Z","rank":12,"volume":null},{"captured_at":"2026-09-30T21:59:12.100602Z","rank":22,"volume":null},{"captured_at":"2026-09-30T23:21:12.042922Z","rank":25,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQcG9WWm5rNTJKbjJBY2dvQ0pHOFdFYjRoSTdTbm4telhPNkMxSjh4N01tYTFBd1N5cHA2ZDBob2l0bHpaYmdHelhJbXdaQXVTV0VmRnlPS2dvLTRwaFBoOFNBbUJkcEVJZzVaenZhQXlsbnBGbmJoVHdpeG44MTFWUVczMTBXN0JHWHhiQVM0T3FTem1ZX2xDWTk5X3ZFSC14R1VVa1pLRVhKX0xHSTBCc0FUSjdJZGlGTURaTjVEMENLMEE?oc=5","author":"www.hlc.com","title":"Pharmacy compounding under the EU pharma law package – What marketing authorisation holders and innovators need to know","snippet":null,"posted_at":"2026-09-30T17:31:02Z","likes":null}],"elsewhere":[],"window":"7d"}}